Nothing Special   »   [go: up one dir, main page]

CY1124212T1 - Εξουδετερωση ανασταλτικων μονοπατιων σε λεμφοκυτταρα - Google Patents

Εξουδετερωση ανασταλτικων μονοπατιων σε λεμφοκυτταρα

Info

Publication number
CY1124212T1
CY1124212T1 CY20211100401T CY211100401T CY1124212T1 CY 1124212 T1 CY1124212 T1 CY 1124212T1 CY 20211100401 T CY20211100401 T CY 20211100401T CY 211100401 T CY211100401 T CY 211100401T CY 1124212 T1 CY1124212 T1 CY 1124212T1
Authority
CY
Cyprus
Prior art keywords
lymphocytes
neutralization
inhibitory pathways
neutralizing agents
treatment
Prior art date
Application number
CY20211100401T
Other languages
English (en)
Inventor
Pascale Andre
Mathieu Blery
Caroline DENIS
Carine Paturel
Nicolai Wagtmann
Original Assignee
Innate Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=57944387&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CY1124212(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Innate Pharma filed Critical Innate Pharma
Publication of CY1124212T1 publication Critical patent/CY1124212T1/el

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

Η εφεύρεση σχετίζεται με τη χρήση παραγόντων εξουδετέρωσης NKG2A για τη θεραπεία καρκίνων που είναι κακώς αποκρινόμενοι σε παράγοντες εξουδετέρωσης PD-1, όπως επίσης και στη συνδυαστική χρήση παραγόντων εξουδετέρωσης NKG2A και παραγόντων εξουδετέρωσης PD-1 για τη θεραπεία του καρκίνου.
CY20211100401T 2016-01-21 2021-05-11 Εξουδετερωση ανασταλτικων μονοπατιων σε λεμφοκυτταρα CY1124212T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662281217P 2016-01-21 2016-01-21
PCT/EP2017/051153 WO2017125532A1 (en) 2016-01-21 2017-01-20 Neutralization of inhibitory pathways in lymphocytes

Publications (1)

Publication Number Publication Date
CY1124212T1 true CY1124212T1 (el) 2022-05-27

Family

ID=57944387

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20211100401T CY1124212T1 (el) 2016-01-21 2021-05-11 Εξουδετερωση ανασταλτικων μονοπατιων σε λεμφοκυτταρα

Country Status (22)

Country Link
US (3) US10870700B2 (el)
EP (2) EP3868787A1 (el)
JP (3) JP7301538B2 (el)
KR (1) KR20180101549A (el)
CN (2) CN108884163B (el)
AU (2) AU2017208554B2 (el)
CA (1) CA3012055A1 (el)
CY (1) CY1124212T1 (el)
DK (1) DK3405495T3 (el)
ES (1) ES2871112T3 (el)
HR (1) HRP20210778T1 (el)
HU (1) HUE054356T2 (el)
IL (1) IL260464B (el)
LT (1) LT3405495T (el)
PL (1) PL3405495T3 (el)
PT (1) PT3405495T (el)
RS (1) RS61901B1 (el)
RU (1) RU2769569C2 (el)
SG (2) SG11201805831RA (el)
SI (1) SI3405495T1 (el)
SM (1) SMT202100280T1 (el)
WO (1) WO2017125532A1 (el)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
CA2838220C (en) 2011-06-17 2020-07-21 Novo Nordisk A/S Use of nkg2a antibodies for treatment of bone loss
CA2974651A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
NZ767837A (en) 2014-09-16 2024-09-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents
JP6944925B2 (ja) 2015-07-24 2021-10-06 イナート・ファルマ・ソシエテ・アノニムＩｎｎａｔｅ Ｐｈａｒｍａ Ｐｈａｒｍａ Ｓ．Ａ． 組織浸潤ｎｋ細胞を検出する方法
KR20200133233A (ko) 2018-03-13 2020-11-26 이나뜨 파르마 두부경부암의 치료
US20210024633A1 (en) * 2018-03-28 2021-01-28 Ensemble Group Holdings Methods of treating cancer in subjects having dysregulated lymphatic systems
SG11202011117VA (en) * 2018-05-15 2020-12-30 Medimmune Ltd Treatment of cancer
AU2019380307A1 (en) * 2018-11-16 2021-07-01 Bristol-Myers Squibb Company Anti-NKG2A antibodies and uses thereof
EP4045535A1 (en) * 2019-10-14 2022-08-24 Innate Pharma Treatment of cancer with ilt-2 inhibitors
JP2023537396A (ja) * 2020-08-12 2023-08-31 ビオンド バイオロジクス リミテッド Ｉｌｔ２に対する抗体およびその使用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
GB9725764D0 (en) 1997-12-04 1998-02-04 Isis Innovation HLA-E binding
AU2003232456B2 (en) 2002-05-30 2009-06-04 Macrogenics, Inc. CD16A binding proteins and use for the treatment of immune disorders
CN102977213B (zh) * 2004-12-28 2017-05-24 依奈特制药公司 抗nkg2a 的单克隆抗体
EP3530736A3 (en) 2005-05-09 2019-11-06 ONO Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1 (pd-1) and methods for treating cancer using anti-pd-1 antibodies alone or in combination with other immunotherapeutics
SG163554A1 (en) 2005-07-01 2010-08-30 Medarex Inc Human monoclonal antibodies to programmed death ligand 1 (pd-l1)
DK2426150T3 (en) * 2006-06-30 2018-01-22 Novo Nordisk As ANTI-NKG2A ANTIBODIES AND APPLICATIONS THEREOF
US8354509B2 (en) 2007-06-18 2013-01-15 Msd Oss B.V. Antibodies to human programmed death receptor PD-1
WO2009014708A2 (en) 2007-07-23 2009-01-29 Cell Genesys, Inc. Pd-1 antibodies in combination with a cytokine-secreting cell and methods of use thereof
RU2010133892A (ru) 2008-01-24 2012-02-27 Ново Нордиск А/С (DK) Гуманизированные моноклональные антитела против человеческого nkg2a
DK2242773T3 (en) 2008-02-11 2017-09-25 Cure Tech Ltd Monoclonal antibodies for tumor treatment
EP2262837A4 (en) 2008-03-12 2011-04-06 Merck Sharp & Dohme PD-1 BINDING PROTEINS
SG172059A1 (en) 2008-12-09 2011-07-28 Genentech Inc Anti-pd-l1 antibodies and their use to enhance t-cell function
SI2504364T1 (sl) 2009-11-24 2017-11-30 Medimmune Limited Usmerjena vezavna sredstva proti B7-H1
JP2013520476A (ja) 2010-02-26 2013-06-06 ノヴォ ノルディスク アー／エス 安定な抗体含有組成物
CN103608040B (zh) 2011-04-20 2017-03-01 米迪缪尼有限公司 结合b7‑h1和pd‑1的抗体和其他分子
CA2838220C (en) 2011-06-17 2020-07-21 Novo Nordisk A/S Use of nkg2a antibodies for treatment of bone loss
TR201820873T4 (tr) 2011-08-01 2019-01-21 Hoffmann La Roche Pd-1 ekseni bağlayıcı antagonistler ve mek inhibitörlerinin kullanıldığı kanser tedavisine yönelik yöntemler.
MX370449B (es) 2013-12-12 2019-12-13 Shanghai hengrui pharmaceutical co ltd Anticuerpo pd-1, fragmento de unión al antígeno de este y uso médico de este.
RU2017105425A (ru) 2014-08-28 2018-09-28 Академиш Зикенхёйс Лейден Х.О.Д.Н. Люмк Комбинации антитела против cd94/nkg2a и/или cd94/nkg2b и вакцины
SG10202007781TA (en) 2014-09-16 2020-09-29 Innate Pharma Treatment Regimens Using Anti-NKG2A Antibodies
NZ767837A (en) 2014-09-16 2024-09-27 Innate Pharma Neutralization of inhibitory pathways in lymphocytes
EP3209687A1 (en) 2014-10-23 2017-08-30 Innate Pharma Treatment of cancers using anti-nkg2a agents

Also Published As

Publication number Publication date
RU2769569C2 (ru) 2022-04-04
KR20180101549A (ko) 2018-09-12
JP2019506391A (ja) 2019-03-07
CN108884163A (zh) 2018-11-23
RS61901B1 (sr) 2021-06-30
LT3405495T (lt) 2021-08-10
EP3405495A1 (en) 2018-11-28
CN108884163B (zh) 2022-08-16
EP3868787A1 (en) 2021-08-25
DK3405495T3 (da) 2021-05-17
HUE054356T2 (hu) 2021-09-28
EP3405495B1 (en) 2021-02-24
AU2017208554B2 (en) 2024-02-15
JP7301538B2 (ja) 2023-07-03
SG11201805831RA (en) 2018-08-30
RU2018125490A3 (el) 2020-06-26
ES2871112T3 (es) 2021-10-28
SG10202000645SA (en) 2020-03-30
US20190031755A1 (en) 2019-01-31
AU2017208554A1 (en) 2018-08-09
SMT202100280T1 (it) 2021-07-12
US20210122821A1 (en) 2021-04-29
US10870700B2 (en) 2020-12-22
WO2017125532A1 (en) 2017-07-27
CN116327916A (zh) 2023-06-27
JP2023134490A (ja) 2023-09-27
PT3405495T (pt) 2021-05-14
AU2024202552A1 (en) 2024-05-16
PL3405495T3 (pl) 2021-10-11
CA3012055A1 (en) 2017-07-27
HRP20210778T1 (hr) 2021-07-23
SI3405495T1 (sl) 2021-08-31
JP7531667B2 (ja) 2024-08-09
IL260464B (en) 2022-02-01
JP2024147818A (ja) 2024-10-16
US20230303691A1 (en) 2023-09-28
RU2018125490A (ru) 2020-02-21

Similar Documents

Publication Publication Date Title
CY1124212T1 (el) Εξουδετερωση ανασταλτικων μονοπατιων σε λεμφοκυτταρα
CY1122981T1 (el) Συνθεσεις για διαμορφωση της εκφρασης του c9orf72
CY1123561T1 (el) Ενωσεις χρησιμες ως αναστολεις κινασης
CY1123827T1 (el) Εξουδετερωση ανασταλτικων οδων σε λεμφοκυτταρα
CY1121542T1 (el) Μορια αντισωματων σε pd-1 και χρηση αυτων
CY1122510T1 (el) Μορια αντισωματος σε lag-3 και χρησεις αυτων
CY1125358T1 (el) Θεραπεια συνδυασμου η οποια περιλαμβανει εναν mdm2 αναστολεα και εναν ή περισσοτερους επιπροσθετους φαρμακευτικως δραστικους παραγοντες για την αντιμετωπιση καρκινων
CY1124891T1 (el) Pd-1/pd-l1 αναστολεις
CY1122721T1 (el) Αντισωματα που δεσμευουν αχl
CY1123557T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της δραστηριοτητας της αργινασης
CY1122329T1 (el) Anti-siglec-8 αντισωματα και μeθοδοι χρhσεως αυτων
CY1122243T1 (el) Παραγωγα ν-πυριδiνυλικoυ ακεταμιδιου ως αναστολεις της οδου σηματοδοτησης wnt
CY1122314T1 (el) Κυκλοπροπυλαμινες ως αναστολεις lsd1
CY1124292T1 (el) Συνθεσεις για τροποποιηση της εκφρασης tau
CY1124407T1 (el) Ενωσεις αναστολεα αυτοταξινης
CY1124483T1 (el) Συνθεσεις και μεθοδοι για την αναστολη της δραστικοτητας της αργινασης
CY1121925T1 (el) Συνδυαστικη θεραπεια με ενα ενζυμο που αποδομει την υαλουρονανη και εναν αναστολεα σημειων ανοσολογικου ελεγχου
CY1121299T1 (el) Υποκατεστημενες τρικυκλικες ενωσεις ως αναστολεις fgfr
CY1121197T1 (el) Il2rbhta/koinhς γαμμα αλυσου αντισωματα
CY1121546T1 (el) Ανθρωποποιημενα αντισωματα εναντι liv-1 και χρηση των ιδιων στην αγωγη του καρκινου
CL2018001152A1 (es) Composiciones y métodos para el tratamiento del cáncer
BR112018003269A2 (pt) conjugados de fármaco-anticorpo anti-dll3 e métodos de utilização
EP3706762A4 (en) N4-HYDROXYCYTIDINE AND DERIVATIVES AND THEIR ANTI-VIRAL USES
CY1120452T1 (el) Παραγωγο αμιδιου πυραζολης
CY1120582T1 (el) Φαρμακευτικες συνθεσεις για την αγωγη παθησεων μεσολαβουμενων απο ρυθμιστη διαμεμβρανικης αγωγιμοτητας κυστικης ινωσης